Showing 3651-3660 of 4164 results for "".
- FDA Approves Anti-Malarial Drugs Chloroquine And Hydroxychloroquine For Emergency Coronavirus Treatmenthttps://modernod.com/news/fda-approves-anti-malarial-drugs-chloroquine-and-hydroxychloroquine-for-emergency-coronavirus-treatment/2477496/The Food and Drug Administration on Sunday issued an emergency authorization for experimental coronavirus treatments using chloroquine and hydroxychloroquine, anti-malaria drugs touted by President Donald Trump despite inconclusive clinical proof of their effectiveness, according to a Forbes
- ImprimisRx to Provide Healthcare Professionals With Telemedicine Serviceshttps://modernod.com/news/imprimisrx-to-provide-healthcare-professionals-with-telemedicine-services/2477446/ImprimisRx, a wholly-owned subsidiary of Harrow Health, announced that they have entered into an exclusive agreement with Doxy.me, a full-service telemedicine solution. The agreement will provide all ImprimisRx ophthalmology, optometry, and wellness practices with the Clinic level
- HIV Drug Failed to Help Patients With Severe Cases of COVID-19https://modernod.com/news/hiv-drug-failed-to-help-patients-with-severe-cases-of-covid-19/2477425/A potential coronavirus treatment has failed in a randomized clinical trial in China. A group of Chinese researchers tested the HIV drug Kaletra in a group of patients with severe cases of COVID-19, the disease caused by the novel coronavirus, according to a
- Roche Initiates Phase 3 Trial of Actemra/RoActemra in Patients With Severe COVID-19 Pneumoniahttps://modernod.com/news/roche-initiates-phase-3-trial-of-actemra-roactemra-in-patients-with-severe-covid-19-pneumonia/2477410/Roche announced it is working with the FDA to initiate a randomized, double-blind, placebo-controlled phase 3 clinical trial in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a part of the US Health and Human Services Office of th
- Verana Health Appoints Veteran Cardiologist Matthew Roe, MD, as Chief Medical Officerhttps://modernod.com/news/verana-health-appoints-veteran-cardiologist-matthew-roe-md-as-chief-medical-officer/2477312/Verana Health announced the appointment of Matthew Roe, MD, MHS, as Chief Medical Officer. A cardiologist and clinical researcher, Dr. Roe joins Verana Health after spending over 2 decades at the Duke University Schoo
- LumiThera to Expand Research into Diabetic Retinopathy for Valeda Light Delivery Systemhttps://modernod.com/news/lumithera-to-expand-research-into-diabetic-retinopathy-for-valeda-light-delivery-system/2477299/LumiThera announced it has initiated further studies with the University of Wisconsin-Milwaukee to establish the use of their Photobiomodulation platform in diabetic retinopathy (DR). “Recent research in our labs in both preclinical and clinical areas hav
- Treat-and-Extend Approach With Ranibizumab Effective in AMDhttps://modernod.com/news/treat-and-extend-approach-with-ranibizumab-effective-in-amd/2477253/In patients with neovascular age-related macular disease, a treat-and-extend ranibizumab regimen is not inferior to injections given at fixed intervals, plus it’s more convenient, according to a new clinical trial, according to a Reuters
- Tarsius Pharma Announces Granting of Orphan Drug Designation for TRS by the European Medicines Agencyhttps://modernod.com/news/tarsius-pharma-announces-granting-of-orphan-drug-designation-for-trs-by-the-european-medicines-agency/2477104/Tarsius Pharma announced that the European Medicines Agency (EMA) approved the designation of orphan drug for its TRS for treatment of noninfectious uveitis and has acknowledged the clinically relevant advantage for TRS in noninfectious uveitis patients with glaucoma not eligible for corticostero
- Neurolign Acquires of Eye Diagnostic Technology Company Neuro Kineticshttps://modernod.com/news/neurolign-acquires-of-eye-diagnostic-technology-company-neuro-kinetics/2476981/Neurolign Technologies announced the acquisition of Neuro Kinetics of Pittsburgh, Pennsylvania, a provider of clinical eye-tracking and noninvasive neurofunctional diagnostic testing, delivering neurofunctional assessments. Terms of the deal were not disc
- Avedro Announces Schedule of Events at AAOhttps://modernod.com/news/avedro-announces-schedule-of-events-at-aao/2476970/Avedro announced its schedule of scientific and educational programs focused on corneal cross-linking and keratoconus during the American Academy of Ophthalmology annual meeting in San Francisco. Avedro’s presentations and educational events underscore the clinical community’s